erlotinib has been researched along with belinostat in 2 studies
Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (belinostat) | Trials (belinostat) | Recent Studies (post-2010) (belinostat) |
---|---|---|---|---|---|
221 | 0 | 180 | 208 | 30 | 167 |
221 | 0 | 180 | 8 | 0 | 7 |
Protein | Taxonomy | erlotinib (IC50) | belinostat (IC50) |
---|---|---|---|
Histone deacetylase 3 | Homo sapiens (human) | 0.1942 | |
Bromodomain-containing protein 4 | Homo sapiens (human) | 0.027 | |
Cytochrome P450 3A5 | Homo sapiens (human) | 0.2147 | |
Histone deacetylase 4 | Homo sapiens (human) | 1.1602 | |
Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 5.12 | |
Histone deacetylase 1 | Homo sapiens (human) | 0.816 | |
Histone deacetylase 7 | Homo sapiens (human) | 0.0357 | |
Histone deacetylase 2 | Homo sapiens (human) | 0.2401 | |
Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.0357 | |
Histone deacetylase 11 | Homo sapiens (human) | 1.5966 | |
Histone deacetylase 8 | Homo sapiens (human) | 1.2526 | |
Histone deacetylase 6 | Homo sapiens (human) | 1.1946 | |
Histone deacetylase 9 | Homo sapiens (human) | 0.0357 | |
Histone deacetylase 5 | Homo sapiens (human) | 0.0357 | |
Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2147 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
2 other study(ies) available for erlotinib and belinostat
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |